BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OxThera, Inc. Resumes Clinical Development of Hyperoxaluria Therapy


6/7/2012 10:48:03 AM

STOCKHOLM, June 7, 2012 /PRNewswire/ --

OxThera AB, a Stockholm-based privately-held biotechnology company, today announced that it has decided to resume clinical development in primary hyperoxaluria. Together with the company program investigating enteric hyperoxaluria, this announcement bolsters the Company's position as a leader in developing therapy for hyperoxaluria, a debilitating condition that leads to kidney damage and end-stage renal disease, if untreated.

"We are confident to provide confirmatory efficacy data from a pre-clinical study later this year. Following this, we will file clinical trial applications for a study in patients", says Elisabeth Lindner, new CEO of OxThera. "Our mapping of OxThera's previous scientific and clinical findings has elucidated several ways forward", Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria. Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine where enteric elimination of endogenous oxalate is initiated. OxThera is currently discussing a complete clinical development plan for Oxabact® with regulatory agencies in the EU and in the US for the treatment of patients suffering from primary hyperoxaluria.

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including stone formation and calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. The high medical need of PH is unmet to date. Currently, the sole available cure is a combined transplantation of liver and kidneys.

OxThera estimates that there are about 2,000 patients with primary hyperoxaluria in the Western world. Oxabact® holds orphan drug designations in the EU and the US for the treatment of PH.

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of primary hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in enteric hyperoxaluria.

http://www.oxthera.com

SOURCE OxThera



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES